Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

February 29, 2016

Primary Completion Date

April 30, 2025

Study Completion Date

February 28, 2027

Conditions
Acute Myeloid LeukemiaMyelodysplastic Syndrome
Interventions
BIOLOGICAL

MultiTAA-specific T cells

"The 5 dose levels are:~Dose Level 1: 5 x 10e6 cells/m2; Dose Level 2: 1 x 10e7 cells/m2; Dose Level 3: 2 x 10e7 cells/m2; Dose Level Four: 5 x 10e7 cells/m2; Dose Level Five: 1 x 10e8 cells/m2~The T cells are given from 30 days post-HSCT. They are administered by intravenous injection over 1-10 minutes through either a peripheral or central lie.~In patients being treated as adjuvant therapy or if patients with residual disease, have a complete response or stable disease, they will be eligible to receive up to 6 further doses of multiTAA-specific T cells at the same dose as the initial infusions (or below the patient's original dose can be administered) at least 4 weeks apart."

Trial Locations (2)

77030

Houston Methodist Hospital, Houston

Texas Children's Hospital, Houston

All Listed Sponsors
collaborator

The Methodist Hospital Research Institute

OTHER

collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

collaborator

American Society for Blood and Marrow Transplantation (ASBMT)

UNKNOWN

collaborator

Cancer Prevention Research Institute of Texas

OTHER

lead

Baylor College of Medicine

OTHER